According to KFF surgery data, about 1 in 8 individuals in the United States has used GLP-1 medications during their life and currently, approximately 15 million adults (or 6% of the population) are using prescription drugs for weight loss, type 2 diabetes, or lowering the risk of cardiovascular diseases
AstraZeneca plc maintains a presence in the incretin-based therapy market through its established portfolio of DPP-4 inhibitors, while actively evaluating pipeline opportunities in next-generation GLP-1 multi-agonist molecules
Semaglutide (Ozempic, Novo Nordisk, Bagsvrd, Denmark) and tirzepatide (Mounjaro, Eli Lilly and Company, Indianapolis, IN, USA) were used
By six months, roughly 80% have reached that 5% milestone
Heres the pattern healthcare providers tend to see: It often appears early in treatment Its usually mild to moderate It tends to get better as the body adjusts Why does semaglutide cause diarrhea